LIQUID BIOPSY IN GYNECOLOGIC ONCOLOGY: CURRENT STATUS AND FUTURE PERSPECTIVES
Keywords:
liquid biopsy, circulating tumor DNA, gynecologic oncology, ovarian cancer, endometrial cancer.Abstract
Liquid biopsy has rapidly evolved from a research concept into a clinically relevant approach for capturing tumor-derived information through minimally invasive sampling, most commonly from blood but increasingly from other fluids that are highly relevant to gynecologic malignancies. By analyzing circulating tumor DNA (ctDNA), circulating tumor cells, extracellular vesicles, and circulating RNA species, liquid biopsy can complement tissue pathology by offering real-time molecular insights, enabling longitudinal monitoring, and potentially detecting relapse earlier than conventional methods.
Downloads
References
1. Pascual J., Attard G., Bidard F.C., et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group // Annals of Oncology. – 2022. – DOI: 10.1016/j.annonc.2022.05.520. PubMed
2. Martinelli C., et al. Liquid biopsy in gynecological cancers: a translational framework from molecular insights to precision oncology and clinical practice // Journal of Experimental & Clinical Cancer Research. – 2025. PMC
3. Ma L., et al. Liquid biopsy in cancer: current status, challenges and future perspectives // Signal Transduction and Targeted Therapy. – 2024. – DOI: 10.1038/s41392-024-02021-w.
